MLYS vs NGNE: fair value comparison
Mineralys Therapeutics, Inc. and Neurogene Inc. · Updated 2026-10-19
MLYS has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. NGNE has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, MLYS currently ranks higher by quality score.
| MLYS | NGNE | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $20.30 | $23.25 |
| 12-month range | $20.30–$47.33 | $16.37–$42.84 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #252 of 301 Healthcare | #254 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Low | Low |
| RSI zone | Oversold | Neutral |
| 50/200-day trend | Downtrend | Mixed |
| 52-week position | The bottom quarter | The lower-middle quarter |
Full single-stock breakdowns: MLYS fair value analysis · NGNE fair value analysis